Document Type : Original Article(s)
Authors
- Sahar Ravanshad 1
- zohre gerami 2
- Salman Farsi 3
- Mohammadhossein Taherynejad 4
- Sobhan Jalali 3
- Mohsen Aliakbarian 5
- Hassan Mehrad-Majd 6
1 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Residence of Internal Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
5 Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
6 Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
Background: Among long non-coding RNAs, as key regulators in oncogenesis, X-inactive specific transcript (XIST) and Taurine upregulated 1 (TUG1) are frequently reported in various cancers. The aim of this study was to investigate the expression patterns and potential clinicopathological and prognostic relevance of XIST and TUG1 in a cohort of Iranian patients with hepatocellular carcinoma (HCC).
Method: In this cross-sectional study, the expression levels of XIST and TUG1 in paired tumor and adjacent non-tumor liver tissues from 22 HCC patients were assessed using real-time quantitative polymerase chain reaction. Patients were divided into two groups based on high and low expression levels for each gene. Associations with clinicopathological features and overall survival of HCC patients were evaluated using statistical methods including chi-square tests, paired t-tests, Kaplan-Meier analysis, and log-rank tests.
Results: The study results showed that the expression of XIST and TUG1 was not significantly higher in tumor tissues than in adjacent normal tissues (P = 0.369, P = 0.632, respectively). TUG1 expression showed a statistically significant association with tumor node metastasis stage (P = 0.02), but no other clinicopathological parameters were correlated with the expression levels of either gene. Kaplan-Meier analysis revealed no significant difference in overall survival based on high vs. low expression of XIST (P = 0.735) or TUG1 (P = 0.239).
Conclusion: Our study found no significant differential expression of XIST and TUG1 between tumor and adjacent non-tumor tissues in a cohort of Iranian HCC patients. Further studies with larger sample sizes are needed to validate these findings.
Highlights
Sahar Ravanshad (google scholar)
Hassan Mehrad-Majd (google scholar)
Keywords
Main Subjects
Please cite this article as: Ravanshad S, Gerami Z, Farsi S, Taherynejad MH, Jalali S, Aliakbarian M, et al. Clinical Evaluation of LncRNA XIST and TUG1 Expression Levels in Patients with Hepatocellular Carcinoma. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.105663.2243.
- Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. 2023 Jun 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 32644603.
- Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular carcinoma: Risk factors, diagnosis and treatment. Open Access Maced J Med Sci. 2015;3(4):732-6. doi: 10.3889/oamjms.2015.111. PMID: 27275318; PMCID: PMC4877918.
- Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898-907. doi: 10.1038/s12276-020-00527-1. PMID: 33268834; PMCID: PMC8080814.
- Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411-28. doi: 10.1038/s41575-019-0145-7. PMID: 31028350.
- National Guideline Centre (UK). Cirrhosis in Over 16s: Assessment and Management. London: National Institute for Health and Care Excellence (NICE); 2016 Jul. PMID: 27441331.
- Calderon-Martinez E, Landazuri-Navas S, Vilchez E, Cantu-Hernandez R, Mosquera-Moscoso J, Encalada S, et al. Prognostic scores and survival rates by etiology of hepatocellular carcinoma: A review. J Clin Med Res. 2023;15(4):200-7. doi: 10.14740/jocmr4902. PMID: 37187717; PMCID: PMC10181349.
- Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216-29. doi: 10.3748/wjg.v28.i2.216. PMID: 35110946; PMCID: PMC8776528.
- Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(5):870-7. doi: 10.1016/j.cgh.2013.09.053. PMID: 24095974; PMCID: PMC3975698.
- Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol. 2020;10:1316. doi: 10.3389/fonc.2020.01316. PMID: 32923383; PMCID: PMC7456927.
- Sayed GI, Solyman M, El Gedawy G, Moemen YS, Aboul-Ella H, Hassanien AE. Circulating miRNA's biomarkers for early detection of hepatocellular carcinoma in Egyptian patients based on machine learning algorithms. Sci Rep. 2024;14(1):4989. doi: 10.1038/s41598-024-54795-2. PMID: 38424116; PMCID: PMC10904762
- Eun JW, Cheong JY, Jeong JY, Kim HS. A new understanding of long non-coding RNA in hepatocellular carcinoma-from m(6)A modification to blood biomarkers. Cells. 2023;12(18). doi: 10.3390/cells12182272. PMID: 37759495; PMCID: PMC10528438.
- Alessio E, Bonadio RS, Buson L, Chemello F, Cagnin S. A single cell but many different transcripts: A journey into the world of long non-coding RNAs. Int J Mol Sci. 2020;21(1). doi: 10.3390/ijms21010302. PMID: 31906285; PMCID: PMC6982300.
- Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA biology. 2013;10(6):925-33. doi:10.4161/rna.24604.
- Huang Y, Liu N, Wang JP, Wang YQ, Yu XL, Wang ZB, et al. Regulatory long non-coding RNA and its functions. J Physiol Biochem. 2012;68(4):611-8. doi: 10.1007/s13105-012-0166-y. PMID: 22535282; PMCID: PMC7098196.
- DiStefano JK. The emerging role of long noncoding RNAs in human disease. Methods Mol Biol. 2018;1706:91-110. doi: 10.1007/978-1-4939-7471-9_6.
- Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells. Oncol Lett. 2019;18(5):4393-402. doi: 10.3892/ol.2019.10848.
- Yang J, Qi M, Fei X, Wang X, Wang K. Long non-coding RNA XIST: a novel oncogene in multiple cancers. Mol Med. 2021;27(1):159. doi: 10.1186/s10020-021-00421-0.
- Zhang M, Yang H, Chen Z, Hu X, Wu T, Liu W. Long noncoding RNA X-inactive-specific transcript promotes the secretion of inflammatory cytokines in LPS stimulated astrocyte cell via sponging miR-29c-3p and regulating nuclear factor of activated T cell 5 expression. Front Endocrinol. 2021;12:573143. doi:10.3389/fendo.2021.573143. PMID: 33776905; PMCID: PMC7995889.
- Farzaneh M, Ghasemian M, Ghaedrahmati F, Poodineh J, Najafi S, Masoodi T, et al. Functional roles of lncRNA-TUG1 in hepatocellular carcinoma. Life Sci. 2022;308:120974. doi: 10.1016/j.lfs.2022.120974. PMID: 36126725.
- Huang MD, Chen WM, Qi FZ, Sun M, Xu TP, Ma P, et al. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Mol Cancer. 2015;14:165. doi: 10.1186/s12943-015-0431-0. PMID: 26336870; PMCID: PMC4558931.
- Dong Z, Yang J, Zheng F, Zhang Y. The expression of lncRNA XIST in hepatocellular carcinoma cells and its effect on biological function. J BUON. 2020;25(5):2430-2437. PMID: 33277866.
- Ma W, Wang H, Jing W, Zhou F, Chang L, Hong Z, et al. Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41(2):163-70. doi: 10.1016/j.clinre.2016.09.002. PMID: 27776968.
)